Long-term oncologic outcomes of robot-assisted radical cystectomy (RARC) with totally intracorporeal urinary diversion (ICUD): a multi-center study.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 18 04 2019
accepted: 03 06 2019
pubmed: 14 6 2019
medline: 29 1 2021
entrez: 14 6 2019
Statut: ppublish

Résumé

To report survival outcomes after robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) for recurrent/muscle-invasive non-metastatic bladder cancer. Prospectively maintained databases were queried for "robotic cystectomy AND ICUD". Patients treated after October 2013 and those treated without curative intent were excluded. Kaplan-Meier method was used to plot stage-specific survival outcomes, computed at 1, 2, and 5 years after surgery. Univariable and multivariable Cox analyses assessed predictors of recurrence-free (RFS), cancer-specific (CSS) and overall (OS) survival. 113 consecutive patients were included, mostly men (82%). Neoadjuvant chemotherapy was performed in 23% of cases, median lymph node (LN) yield was 36 (IQR 28-45) and the rate of positive surgical margins (PSM) was 8%. Orthotopic ileal neobladder was the preferred ICUD type (57%). An organ-confined disease was observed in 51% of cases and 21% were pT0 on final histology. Overall, 5-year RFS, CSS and OS probabilities were 58 ± 5%, 61 ± 5% and 54 ± 5%, respectively. At Kaplan-Meier method, tumor stage group was a significant predictor of survival probabilities (all p < 0.001) and this was confirmed at multivariable Cox regression analysis (RFS-OR 2.29; 95% CI 1.58-3.32; p < 0.001) (CSS-OR 1.82; 95% CI 1.3-2.53; p < 0.001) (OS-OR 2.14; 95% CI 1.46-3.14; p < 0.001). PSM status was associated to CSS (OR 2.54; 95% CI 1.13-5.69; p = 0.024) and OS (OR 2.82; 95% CI 1.17-6.77; p = 0.021), but did not predict RFS (p = 0.062). Long-term oncologic outcomes after RARC with ICUD appear similar to recent robotic series with extracorporeal diversion and historical open experiences.

Identifiants

pubmed: 31190152
doi: 10.1007/s00345-019-02842-3
pii: 10.1007/s00345-019-02842-3
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

837-843

Références

Urology. 2013 Dec;82(6):1323-9
pubmed: 24295248
BJU Int. 2011 Feb;107(4):642-6
pubmed: 20575975
Eur Urol. 2015 Mar;67(3):376-401
pubmed: 25560798
BJU Int. 2002 Sep;90(4):391-6
pubmed: 12175395
Eur Urol. 2015 Oct;68(4):721-8
pubmed: 25985883
Eur Urol. 2018 Oct;74(4):465-471
pubmed: 29784190
BJU Int. 2018 May;121(5):752-757
pubmed: 29281852
Arch Pathol Lab Med. 2019 May;143(5):571-577
pubmed: 30044124
J Robot Surg. 2020 Apr;14(2):261-269
pubmed: 31124038
J Endourol. 2014 Aug;28(8):939-45
pubmed: 24635448
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Lancet. 2018 Jun 23;391(10139):2525-2536
pubmed: 29976469
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
BJU Int. 2017 Jan;119(1):185-191
pubmed: 27474790
Eur Urol. 2015 Mar;67(3):402-22
pubmed: 25560797
Eur J Surg Oncol. 2018 Sep;44(9):1432-1438
pubmed: 29699838
J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267
pubmed: 28982750
Eur Urol. 2012 Nov;62(5):891-901
pubmed: 22920581
BJU Int. 2014 Jan;113(1):11-23
pubmed: 24330062
Eur Urol. 2014 Feb;65(2):340-7
pubmed: 24183419
World J Urol. 2018 Nov;36(11):1711-1718
pubmed: 29744571
J Urol. 2012 Dec;188(6):2139-44
pubmed: 23083864
Urol Oncol. 2016 Jun;34(6):257.e1-9
pubmed: 26968561
Urol Oncol. 2013 Nov;31(8):1621-7
pubmed: 22534088
Scand J Urol. 2016;50(1):39-46
pubmed: 26313582
Eur Urol. 2016 Apr;69(4):613-621
pubmed: 26272237
Eur Urol. 2014 Nov;66(5):920-8
pubmed: 24768522
Eur Urol. 2019 Apr;75(4):612-614
pubmed: 30616946
Eur Urol. 2019 Apr;75(4):604-611
pubmed: 30337060
Int J Urol. 2013 Apr;20(4):390-7
pubmed: 22970939
Eur Urol. 2018 Jun;73(6):934-940
pubmed: 27780643
J Urol. 2007 Mar;177(3):876-81; discussion 881-2
pubmed: 17296365

Auteurs

Aldo Brassetti (A)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. aldo.brassetti@gmail.com.

Giovanni Cacciamani (G)

Department of Urology, University of Southern California, Los Angeles, CA, USA.

Umberto Anceschi (U)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Mariaconsiglia Ferriero (M)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Gabriele Tuderti (G)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Gus Miranda (G)

Department of Urology, University of Southern California, Los Angeles, CA, USA.

Riccardo Mastroianni (R)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Mihir Desai (M)

Department of Urology, University of Southern California, Los Angeles, CA, USA.

Monish Aron (M)

Department of Urology, University of Southern California, Los Angeles, CA, USA.

Inderbir Gill (I)

Department of Urology, University of Southern California, Los Angeles, CA, USA.

Michele Gallucci (M)

Department of Urology, "Sapienza" University of Rome, Rome, Italy.

Giuseppe Simone (G)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH